By the Numbers: Private Payers and Specialty Pharmaceuticals

Written By Allison Wills

April 18, 2022

Share on LinkedIn

The specialty pharmaceutical sector, which caters to patients with complex conditions requiring sophisticated and often costly treatments, depends on private payers to survive and thrive – and the private-payer commitment keeps growing.

Private Payer Landscape in Canada

70%: Proportion of Canadians with private/supplementary health insurance – that’s 26 million people.1

100K+: Number of private drug benefit plans, usually offered as employment benefits but also available for direct sale to individuals.2

36.9%: Share of total drug-spend carried by private payers, approaching the 43.6% funded by the public system.3 In the US, private payers absorb a very similar proportion (42%) of drug costs, challenging the notion that Canada leans far more heavily on the public purse.4

$12.7B: Cumulative cost of prescription drugs covered by private plans in 2021.1

Private Payers and Specialty Drugs

32%: Total private payer drug costs devoted to specialty drugs – approximately $4B as of early 2021.5 These costs are associated with just 1.3% of patients.6

8.7%: Increase in specialty drug spend in the private payer space in 2020,5, more than 6 times the increase (1.3%) in conventional drug expenditures.6

2.5%: Increase in the cost per private payer claim for a specialty drug in 2020. In contrast, the average cost of a traditional drug claim decreased by 0.8% during this period.5

Specialty Therapeutic Areas Covered by Private Payers

44.4%: Proportion of costs devoted to rheumatoid arthritis, inflammatory bowel disease, and psoriasis among the top 1% of high-cost private payer claims in 2021.6

80%: Share of oncology drug costs allotted to oral medications within the private payer sphere – significantly higher than the overall figure of 50% in Canada.7

100% Double: Increase in the cost per oncology drug claim in private plans between 2010 and 2019, compared to just 5% for non-oncology drugs.7

> 50%: Proportion of oncology drugs in the pipeline designed for oral administration.8

> $650M: Amount paid out by insurers to cover rare disease drugs in 2020.1

32%: Growth in private payer expenditures for rare disease drugs in Canada between 2012 and 2019.1

References

  1. Mirror, mirror 2021: reflecting poorly. A report by the Commonwealth Fund, Aug. 4, 2021. https://www.commonwealthfund.org/publications/fund-reports/2021/aug/mirror-mirror-2021-reflecting-poorly#rank

  2. OECD interactive tool: International comparisons – peer countries. CIHI. https://www.cihi.ca/en/oecd-interactive-tool-international-comparisons-peer-countries-canada

  3. Hoskyn SL. Explaining public reimbursement delays for new medicines for Canadian patients. Innovative medicines Canada.

  4. Cancer Can’t Wait Virtual Action webinar, week #2. Canadian Cancer Survivor Network. Dec. 9, 2021.

  5. COVID-19 expected to push Canada’s health spending beyond $300 billion in 2021. CIHI. Nov. 4, 2021. https://www.cihi.ca/en/covid-19-expected-to-push-canadas-health-spending-beyond-300-billion-in-2021

  6. U of T researchers to help form Coronavirus Variants Rapid Response Network. U of T News. March 29, 2021. https://www.utoronto.ca/news/u-t-researchers-help-form-national-coronavirus-variants-rapid-response-network

  7. Health Canada authorizes the first Covid-19 vaccine. Government of Canada. Dec. 9, 2021. https://www.canada.ca/en/health-canada/news/2020/12/health-canada-authorizes-first-covid-19-vaccine0.html

  8. Aiello R. Historic moment: Health Canada approves Pfizer Covid-19 vaccine. CTV News. Dec. 9, 2021. https://www.ctvnews.ca/health/coronavirus/historic-moment-health-canada-approves-pfizer-covid-19-vaccine-1.5223477

  9. Covid-19 vaccination in Canada: vaccination coverage. Government of Canada. Last updated Nov. 26, 2021, with data up to Nov. 20. https://health-infobase.canada.ca/covid-19/vaccination-coverage/

  10. 2021 national survey of Canadian physicians. Canadian Health Infoway. Aug. 9, 2021. https://www.infoway-inforoute.ca/en/component/edocman/resources/reports/benefits-evaluation/3935-2021-national-survey-of-canadian-physicians

  11. McGillion MH et al. Post-discharge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomised controlled trial. BMJ 2021;374:n2209.

  12. Consumer engagement with digital is shifting. Data from STI.

  13. Magalon T et al. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer incidence and mortality in Canada. MedRxiv preprint, Aug. 28, 2021. https://www.medrxiv.org/content/10.1101/2021.08.26.21261149v1.

  14. Letter to the Canadian Government. Canadian Association of Rare Diseases. April 26, 2021. http://www.raredisorders.ca/content/uploads/CORD-PM-MOH-Rare-Drug-Strategy-0422021v2.pdf

Allison Wills
Previous

Making Meaning from Numbers
Next

Better Value, Better Health